Analyst Price Targets — EDIT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| November 5, 2024 10:23 am | Gena Wang | Barclays | $5.00 | $3.12 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $5 at Barclays |
| October 23, 2024 6:36 am | Yanan Zhu | Wells Fargo | $9.00 | $3.29 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $9 at Wells Fargo |
| October 22, 2024 1:41 pm | Joel Beatty | Robert W. Baird | $10.00 | $3.29 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $10 at Baird |
| August 8, 2024 7:24 am | Joon Lee | Truist Financial | $12.00 | $4.24 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $12 at Truist Securities |
| August 8, 2024 6:44 am | Greg Harrison | Bank of America Securities | $15.00 | $4.21 | StreetInsider | BofA Securities Upgrades Editas Medicine (EDIT) to Buy |
| May 30, 2024 6:02 am | Liisa Bayko | Evercore ISI | $7.00 | $5.10 | StreetInsider | Editas Medicine (EDIT) PT Lowered to $7 at Evercore ISI |
| May 9, 2024 12:34 am | Matthew Harrison | Morgan Stanley | $7.00 | $5.04 | StreetInsider | Morgan Stanley Upgrades Editas Medicine (EDIT) to Equalweight |
| September 28, 2023 4:38 pm | Dae Gon Ha | Stifel Nicolaus | $17.00 | $6.92 | StreetInsider | Stifel Upgrades Editas Medicine (EDIT) to Buy, 'Difficult To Justify Current Valuation' |
| December 13, 2022 1:10 pm | — | Citigroup | $11.00 | $9.96 | Benzinga | Citigroup Initiates Coverage On Editas Medicine with Neutral Rating, Announces Price Target of $11 |
| November 18, 2022 7:59 am | — | Morgan Stanley | $8.00 | $10.64 | Benzinga | Morgan Stanley Maintains Underweight on Editas Medicine, Lowers Price Target to $8 |
Latest News for EDIT
Editas Medicine to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in March:
Genflow Biosciences PLC Announces Directorate Change
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.